Product news from the 10/31/06 News Brief

Share this article:
The FDA has approved Novartis’ Tyzeka (telbivudine) for patients with chronic hepatitis B. Alpharma won FDA approval for its 80 mg dosage strength of chronic pain treatment Kadian (morphine sulfate). The company expects to launch this new dosage strength during the fourth-quarter of 2006. Kadian is currently marketed in 20mg, 30mg, 50mg, 60mg and 100mg dosages.
Share this article:
You must be a registered member of MMM to post a comment.

Does a health psychology approach hold the key to Rx adherence? In MM&M's latest Leadership Exchange Uncut eBook, industry stakeholders from the payer, provider, academic and pharma realms explore the "why" behind medicine taking. Access here.